The next generation of chemotherapies will target cancer cells more effectively than many current chemotherapies, which can cause unwanted side effects by attacking both normal and cancer cells.
Femtogenix is an established drug discovery startup specialising in the development of payloads - one of three key components in a group of targeted chemotherapies known as antibody-drug conjugates (ADCs).
Payloads are molecules that are toxic to living cells and kill cancer cells. When combined with antibodies to target cancer cells, and a linker to bring all these molecules together, it creates a highly effective, targeted cancer treatment that is less likely to cause side effects.
Femtogenix’s discovery platform uses computational chemistry and state-of-the-art synthetic chemistry methodologies to both design and synthesise payload molecules that can bind to DNA and effectively kill cancer cells at low concentrations.
Paul Jackson co-founded the company and helps lead its scientific and commercial strategy as it refines its core technology. With support from the SME Leaders Programme, Paul aims to learn from a network of entrepreneurs and strengthen his leadership skills as the company expands and establishes its technology to support the development of ADCs in this rapidly growing field.